Founded in 2013, Vali Nanomedical focuses on creating programmable delivery systems for therapeutics and imaging agents. Through partnerships with pharmaceutical companies, they have developed a novel imaging agent and are working towards curing diseases without the use of drugs. Their technology can reprogram cancerous cells to commit suicide, allowing healthier cells to replace them. Vali Nanomedical's multidrug-delivery platform technology offers an unprecedented level of specificity, efficacy, and safety in cancer therapies.